The budget reconciliation bill, known as the One Big Beautiful Bill (OBBB), a broad spending and tax bill that includes significant healthcare policies, is now on its way to President Trump after ...

ASCO’s Leadership Development Program (LDP) prepares you to become a leader while giving you exclusive access to ASCO leaders and the broader oncology community, as well as a robust network of past ...

A new article in JCO Oncology Practice (JCO OP) looks at the root causes of cancer drug shortages in the United States (U.S.), the impact of these shortages on patients and providers, and makes ...

On June 20, 2025, the Centers for Medicare & Medicaid Services (CMS) released the 2025 Marketplace Integrity and Affordability final rule aimed at addressing improper enrollments in the ACA Health ...

America’s Health Insurance Plans (AHIP)—a trade group representing the U.S. health insurance industry—announced a commitment from participating plans to improve prior authorization processes. The ...

Medicare Advantage Audits Are Expanding. What Do Oncology Practices Need to Know? Continuing its efforts to reduce fraud, waste, and abuse in Medicare, the Centers for Medicare & Medicaid Services ...

American Society of Clinical Oncology (ASCO) and Egyptian Cancer Society (ECS) leaders signed a Memorandum of Understanding (MOU) on June 2, 2025, during ASCO’s 61st Annual Meeting. The MOU formally ...

American Society of Clinical Oncology Choosing Wisely; Last Reviewed 2021 ASCO's 2021 Top Five List in Oncology The American Society of Clinical Oncology (ASCO) is a medical professional oncology ...

All Conquer Cancer research grant applications are carefully reviewed and evaluated by an independent Grants Selection Committee (Committee) using consistent criteria across all applications for each ...

All International Development and Education Award (IDEA) applications are carefully reviewed and evaluated by the IDEA Steering Group. The Steering Group scores and ranks the applications using ...

If you are looking for non-scientific summaries for patients, please visit the Patient Information page. TAPUR Study Analysis Plan The TAPUR Study is a phase II, non-randomized, open-label clinical ...